Agenus Inc. (NASDAQ:AGEN) is reporting third quarter financial results on Thursday 29th October 2020, before market open.
According to analysts surveyed by Thomson Reuters, AGEN is expected to report 3Q20 loss of $ 0.26 per share from revenue of $ 14.00 million.
For the full year, analysts anticipate top line of $ 70.74 million, while looking forward to loss of $ 1.02 per share bottom line.
Previous Quarter Performance
Agenus Inc. disclosed loss for the second quarter of $ 0.28 per share, from the revenue of $ 26.95 million. The quarterly revenues extended 71.55 percent compared with the same quarter last year. Wall street analysts are predicting, AGEN to report 2Q20 loss of $ 0.27 per share from revenue of $ 9.33 million. The bottom line results missed street analysts by $ 0.01 or 3.7 percent, at the same time, top line results outshined analysts by $ 17.62 million or 188.85 percent.
Stock Performance
Shares of Agenus Inc. traded low $ -0.15 or -3.91 percent on Wednesday, reaching $ 3.69 with volume of 1.29 million shares. Agenus Inc. has traded high as $ 3.79 and has cracked $ 3.61 on the downward trend
According to the previous trading day, closing price of $ 3.69, representing a 110.99 % increase from the 52 week low of $ 1.82 and a 31.79 % decrease over the 52 week high of $ 5.63.
The company has a market capital of $ 676.90 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Agenus Inc. will be hosting a conference call at 8:30 AM eastern time on 29th October 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website agenusbio.com
Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the bodys immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. It is also developing checkpoint modulating antibody candidates targeting GITR, OX40, TIM-3, LAG-3, and others.
